Marcus Jewell Sells 12,562 Shares of Cellebrite DI (NASDAQ:CLBT) Stock

Key Points

• Cellebrite CRO Marcus Jewell sold 12,562 shares at an average price of $11.24, generating $141,196.88. Following the transaction, he directly owned 427,128 shares, a 2.86% reduction in his holdings.
• CLBT shares traded at $11.49, near the lower end of their 52-week range of $9.58 to $19.98. The stock’s 50-day and 200-day moving averages were $14.27 and $13.85, respectively.
• Analysts remain broadly positive, with five Buy ratings and one Sell rating and a consensus “Moderate Buy” view, although several firms recently lowered their price targets. Institutional investors own 45.88% of the company.

Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) CRO Marcus Jewell sold 12,562 shares of the firm's stock in a transaction on Friday, August 21st. The stock was sold at an average price of $11.24, for a total value of $141,196.88. Following the completion of the sale, the executive directly owned 427,128 shares of the company's stock, valued at $4,800,918.72. This trade represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Marcus Jewell also recently made the following trade(s):

• On Wednesday, August 12th, Marcus Jewell sold 411 shares of Cellebrite DI stock. The stock was sold at an average price of $16.07, for a total value of $6,604.77.

Cellebrite DI Price Performance

Shares of CLBT traded up $0.44 during mid-day trading on Monday, reaching $11.49. The stock had a trading volume of 3,463,245 shares, compared to its average volume of 2,270,829. Cellebrite DI Ltd. has a 52-week low of $9.58 and a 52-week high of $19.98. The business's fifty day moving average is $14.27 and its 200 day moving average is $13.85. The firm has a market cap of $2.87 billion, a price-to-earnings ratio of 52.23, a P/E/G ratio of 1.53 and a beta of 1.18.

Institutional Trading of Cellebrite DI

Several institutional investors have recently added to or reduced their stakes in the stock. Cooper Creek Partners Management LLC acquired a new position in Cellebrite DI during the 3rd quarter worth about $55,999,000. Capital International Investors purchased a new stake in Cellebrite DI during the fourth quarter worth about $41,073,000. Invesco Ltd. increased its stake in Cellebrite DI by 58.6% during the third quarter. Invesco Ltd. now owns 5,560,196 shares of the company's stock worth $103,030,000 after purchasing an additional 2,054,644 shares during the period. California State Teachers Retirement System lifted its position in shares of Cellebrite DI by 1,595.2% during the second quarter. California State Teachers Retirement System now owns 1,972,752 shares of the company's stock worth $28,802,000 after purchasing an additional 1,856,378 shares in the last quarter. Finally, Weiss Asset Management LP lifted its position in shares of Cellebrite DI by 3,485.3% during the first quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company's stock worth $26,180,000 after purchasing an additional 1,846,851 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company's stock.

Wall Street Analyst Weigh In

CLBT has been the topic of several analyst reports. DA Davidson reduced their price target on shares of Cellebrite DI from $22.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, August 14th. JPMorgan Chase & Co. cut their target price on Cellebrite DI from $20.00 to $16.00 and set an "overweight" rating for the company in a research note on Friday, August 14th. Lake Street Capital decreased their price target on Cellebrite DI from $21.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday, August 14th. Weiss Ratings cut Cellebrite DI from a "hold (c-)" rating to a "sell (d+)" rating in a report on Thursday, August 13th. Finally, Needham & Company LLC cut their price objective on Cellebrite DI from $15.00 to $12.50 and set a "buy" rating for the company in a research report on Friday, August 14th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $16.70.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source